Matthew Taylor
Stock Analyst at UBS
(2.71)
# 2,146
Out of 5,090 analysts
182
Total ratings
61.82%
Success rate
11.24%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Neutral | $320 → $355 | $304.49 | +16.59% | 16 | Nov 7, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $80 → $98 | $86.19 | +13.70% | 20 | Oct 29, 2025 | |
| SI Shoulder Innovations | Initiates: Buy | $19 | $15.20 | +25.00% | 1 | Aug 25, 2025 | |
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $125.08 | +15.93% | 17 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.42 | +4.02% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $85.46 | +20.52% | 2 | Jan 8, 2025 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $101.36 | -25.02% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $1.70 | +7,252.94% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $141.68 | -14.60% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $4.40 | +218.18% | 1 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $45 | $20.92 | +115.11% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $10 | $6.62 | +51.06% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $13.23 | +300.60% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $11.58 | +107.25% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $364.02 | -5.22% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $94.28 | +37.89% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $300.66 | -23.50% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $19.68 | +1.63% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $40.07 | +112.13% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $91.10 | -17.67% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $256.55 | -4.50% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $18.54 | +234.41% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $120.50 | +74.27% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $21.45 | -44.06% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $65.49 | +90.87% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $97.52 | -48.73% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $575.34 | -63.50% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $63.36 | +51.52% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $3.06 | +128.76% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $193.96 | +37.14% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $13.47 | +18.78% | 2 | Jul 19, 2017 |
Insulet
Nov 7, 2025
Maintains: Neutral
Price Target: $320 → $355
Current: $304.49
Upside: +16.59%
Edwards Lifesciences
Oct 29, 2025
Upgrades: Buy
Price Target: $80 → $98
Current: $86.19
Upside: +13.70%
Shoulder Innovations
Aug 25, 2025
Initiates: Buy
Price Target: $19
Current: $15.20
Upside: +25.00%
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $125.08
Upside: +15.93%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.42
Upside: +4.02%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $85.46
Upside: +20.52%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $101.36
Upside: -25.02%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $1.70
Upside: +7,252.94%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $141.68
Upside: -14.60%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $4.40
Upside: +218.18%
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $20.92
Upside: +115.11%
Jul 19, 2023
Initiates: Underperform
Price Target: $10
Current: $6.62
Upside: +51.06%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $13.23
Upside: +300.60%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $11.58
Upside: +107.25%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $364.02
Upside: -5.22%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $94.28
Upside: +37.89%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $300.66
Upside: -23.50%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $19.68
Upside: +1.63%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $40.07
Upside: +112.13%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $91.10
Upside: -17.67%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $256.55
Upside: -4.50%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $18.54
Upside: +234.41%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $120.50
Upside: +74.27%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $21.45
Upside: -44.06%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $65.49
Upside: +90.87%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $97.52
Upside: -48.73%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $575.34
Upside: -63.50%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $63.36
Upside: +51.52%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $3.06
Upside: +128.76%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $193.96
Upside: +37.14%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $13.47
Upside: +18.78%